Exceptional revenue growth near 63% per year and three consecutive earnings beats demonstrate strong commercial momentum, but deeply negative free cash flow consuming roughly 89% of revenues, below-floor business quality, and a technical setup that has not yet confirmed a resumption of trend strength combine to limit the investable case despite the growth trajectory.
Thesis pillars
- Exceptional Revenue Growth Rate→Stable
- Improving Earnings Beat Cadence→Stable
- Severe Cash Burn Viability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $26.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Rich valuation.
Kestra Medical Technologies is a commercial-stage wearable medical device company that developed the ASSURE WCD, a next-generation wearable cardioverter defibrillator for patients at elevated risk of sudden cardiac arrest, alongside a broader Cardiac Recovery System of... Read more
Sell if holding. Engine safety override at $26.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Kestra Medical Technologies, Lt
About Kestra Medical Technologies, Lt
Kestra Medical Technologies markets the ASSURE WCD, a wearable cardioverter defibrillator that received FDA premarket approval in July 2021 and ended a two-decade single-competitor market for wearable defibrillation therapy. The device generated $59.8 million in revenue for the fiscal year ended April 30, 2025, up 115% from $27.8 million in fiscal 2024, with commercial efforts concentrated in the United States even as international WCD industry revenue reached roughly 15% of the global total in 2023.
Kestra generates revenue mainly by leasing the ASSURE WCD to patients on a month-to-month basis and billing third-party payors — Medicare, select state Medicaid programs and national commercial insurers — who together covered over 285 million U.S. lives, or about 90% of available lives, as of April 30, 2025. A commercial team of roughly 80 direct sales representatives and more than 40 clinical support staff, backed by over 300 contracted patient specialists, handles prescribing, fitting and device reprocessing through a lease-and-reprocess supply chain built with top-tier medical technology suppliers. The company's only publicly named competitor is the maker of the prior generation WCD that held the market exclusively for more than 20 years before ASSURE's 2021 approval; Kestra cites a 6% false-alarm rate for its device versus 46% for that competitor's product in its most recent FDA submission.
Show full overview
Kestra's growth case rests almost entirely on the ASSURE WCD: the 10-K states that revenue from the device and its associated Cardiac Recovery System services will account for nearly all of company revenue for the foreseeable future, with no second product line to diversify that exposure. Reimbursement is similarly concentrated with government and commercial payors rather than direct patient payments, and the 10-K cautions that a decline in Medicare or commercial reimbursement rates, or new coverage limitations, could directly impair results — a single-product, third-party-payor-dependent structure uncommon even among early commercial medtech peers.
See also: Healthcare · Medical Instruments & Supplies
From Kestra Medical Technologies, Lt's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — Kestra Medical Technologies, Lt
Latest news
- NEWS Goldman Sachs Maintains Neutral on Kestra Medical Techs, Lowers Price Target to $17 — benzinga Apr 9, 2026 neutral
Generated 2026-07-06T04:40:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductASSURE WCD10-K Item 1A: 'We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -173.0%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.98: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $25.09. Score 4.7/10, moderate confidence.
Take-profit target: $27.34 (+1.3% upside). Prior stop was $25.09. Stop-loss: $25.09.
Concentration risk — Product: ASSURE WCD; Target reached (-10.6% upside); Quality below floor (3.5 < 4.0).
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -12.6). TrendMatrix value score: 1.8/10. Verdict: Sell.
13 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $28.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies is a commercial-stage wearable medical device company that developed the ASSURE WCD, a...
Kestra Medical Technologies is a commercial-stage wearable medical device company that developed the ASSURE WCD, a next-generation wearable cardioverter defibrillator for patients at elevated risk of sudden cardiac arrest, alongside a broader Cardiac Recovery System of monitoring and digital health services. The company leases the ASSURE WCD to patients and bills Medicare, Medicaid and commercial payors, generating $59.8 million in revenue for the fiscal year ended April 30, 2025, up from $27.8 million a year earlier, with a $113.8 million net loss.